

Clinical Design & Innovation; Office of the Chief Clinical Officer Dr Steevens' Hospital, D08 W2A8 E: clinicaldesign@hse.ie

9th July, 2024

Deputy Paul Murphy, TD Dáil Éireann Leinster House Kildare Street Dublin 2

RE: PQ 27910/24

To ask the Minister for Health how the HSE transgender lead plans to take into account bad faith international research produced by those that oppose trans healthcare

Dear Deputy Murphy,

The Health Service Executive has been requested to reply directly to you in relation to the above parliamentary question, which you submitted to the Minister for Health for response. I have consulted with the National Clinical Advisor and Group Lead for Children and Young People (NCAGL C&YP) on your question and have been informed that the following outlines the position.

The National Clinical Lead for the HSE's gender healthcare programme has been appointed and it is planned that this person will commence in the post within the next month.

Over the next two years, the programme will work with a range of stakeholders to develop an updated clinical model of care for gender healthcare services for the Irish population. This model of care will be developed in an open, transparent and consultative way, engaging with stakeholders who will be involved in the design of services and advise on the delivery and evaluation of services.

Emerging and evolving international evidence, including evidence on the use of puberty blockers and reports such as the Cass report from the UK, will be reviewed as part of this work.

The outcome of this work will be informed and guided by the needs of people living in Ireland.

I trust this information is of assistance to you, but should you have any further queries please do not hesitate to contact me.

Yours sincerely

Anne Horgan General Manager

